92161-65-4

Usage

Uses

Used in Organic Synthesis:
Methyl 2-(4-chloro-2-nitrophenylthio)benzoate is used as a key intermediate in the synthesis of a wide range of organic compounds. Its unique structure allows for various chemical reactions, such as nucleophilic substitution, electrophilic aromatic substitution, and reductive dehalogenation, which can be employed to modify its properties and create new molecules with desired characteristics.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, methyl 2-(4-chloro-2-nitrophenylthio)benzoate is utilized as a building block for the development of new drugs. Its versatile chemical properties enable the synthesis of various drug candidates with potential therapeutic applications. For instance, it can be used to create novel antimicrobial agents, anti-inflammatory drugs, or even anticancer compounds.
Used in Agrochemical Industry:
Methyl 2-(4-chloro-2-nitrophenylthio)benzoate also finds application in the agrochemical industry, where it is employed as a precursor for the synthesis of new pesticides and herbicides. Its unique structure can be modified to create molecules with enhanced biological activity and selectivity, leading to the development of more effective and environmentally friendly agrochemicals.
Used in Specialty Chemicals:
In the specialty chemicals sector, methyl 2-(4-chloro-2-nitrophenylthio)benzoate is used as a starting material for the synthesis of various specialty chemicals, such as dyes, pigments, and polymer additives. Its ability to undergo a range of chemical reactions allows for the creation of novel compounds with unique properties and applications.

Upstream product

• 700-37-8 4-chloro-2-fluoro-nitrobenzene 
• 4892-02-8 Methyl thiosalicylate 
• 60-29-7 diethyl ether 
• 17999-25-6 methyl thiosalicylate 
• 89-61-2 2,5-dichloronitrobenzene 
• 345-18-6 2-fluoro-5-chloronitrobenzene 

Downstream Products

• 93535-13-8 2-(2-amino-4-chloro-phenylsulfanyl)-benzoic acid methyl ester 
• 126395-03-7 2-(4-chloro-2-nitrophenylsulfanyl)benzoic acid 
• 1071718-24-5 methyl 2-((2-amino-4-chlorophenyl)thio)benzoate hydrochloride salt 
• 1451261-79-2 2-({2-[(1-benzofuran-2-ylsulfonyl)amino]-4-chlorophenyl}sulfanyl)benzoic acid 
• 3158-80-3 8-chloro-10H-dibenzo[b,f][1,4]thiazepin-11-one 
• 167996-98-7 2-(2-amino-4-chlorophenylsulfanyl)benzoic acid 

Relevant academic research and scientific papers

BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

The present invention relates to novel benzofuran-2-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

AMINO SUBSTITUTED DIARYL[A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS

Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.

IRON CATALYZED CROSS-COUPLING REACTIONS OF IMIDOYL DERIVATIVES

Disclosed is a process for preparing a compound of formula A - N=C(D)(B), from a compound of formula A-N=C(E)(B) and a compound of formula D-M using an iron catalyst, where the process has is represented by Equation (I).

USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS

Disclosed herein is the use of N-desmethylclozapine (NDMC) and related compounds to treat a variety of neuropsychiatric diseases including psychosis. It is shown that NDMC and related compounds are agonists or partial agonists at D2 and D3 dopamine receptors and thus may be effective as a dopamine stabilizing agent, allowing it to be used to treat or provide reduced incidence of Extrapyramidal symptoms (EPS) and/or tardive dyskinesias (TD). Also disclosed is administering NDMC and related compounds in combination with other anti-psychotic agents.

Iron-catalyzed cross-coupling of imidoyl chlorides with Grignard reagents

A general, high yielding rapid iron-catalyzed cross-coupling reaction between Grignard reagents and imidoyl chlorides is described. These reactions are typically completed within 5 min, resulting in high yields of 71-96% using 5% iron catalyst in a THF-NM

AMINO SUBSTITUTED DIARYL[A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS

Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.

BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY

Described herein are D4 receptor-selective compounds of the general formula: STR1 wherein: A and B are independently selected, substituted or unsubstituted, unsaturated 5-or 6-membered, homo-or heterocyclic rings;X 1 is selected from O, S, SO, SO 2, CH. sub.2, C=O, CH--OH, CH--N(C 1-4 alkyl) 2, C= CHCl, and C=CHCN;X 2---is selected from N= , CH. sub.2--, CH= and C(O)--;n is 1 or 2; R 1 is selected from H and the α-carbon side chain of an amino acid;R 2 and R 3 are selected independently from H, OH,--NH 2,--C(O)NH 2 =O, =S,halo, cyano, C 1-9 alkyl, C 1-9 alkoxy, C 1-4 alkylS--, C 1-4 alkylSO--, C 1-4 alkylSO 2--, phenoxy, benzyloxy and piperonyloxy; andH* is in either the R-or the S-configuration,and acid addition salts, solvates and hydrates thereof.Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, is also described.

MUSCARINIC RECEPTOR LIGANDS

Described herein are D4 receptor-selective compounds of the general formula I: STR1 wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5-or 6-membered, homo-or heterocyclic rings;X 1 is selected from CH 2, O, NH, S, C=O, CH--OH, CH--NEt 2, C=CHCl, C=CHCN, N--C. sub.1-4 alkyl, N-acetyl, SO 2 and SO;X 2--is selected from N=, CH 2--, CH=, C(O)--, O--, and S--; n is 1 or 2; andZ is selected from C 1-6 alkyl optionally substituted with a substituent selected from OH, halo, C. sub.1-4 alkyl and C 1-4 alkoxy;and acid addition salts, solvates and hydrates thereof. Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the M1/M2 receptor is implicated, such as schizophrenia, is also described.